Karyopharm extends forbearance period to Nov 1
Item 8.01 Other events
- Form
- 8-K
- Filed
- Importance
- Routine
- Accession
- 0001193125-26-428938
- Forbearance period extended to Nov 1, 2026
- Previous extension was to Oct 22, 2026
- Forbearance Agreement dated Sept 10, 2026
Written from the 8-K on EDGAR. Check the filing before you rely on it.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Abvc Biopharma ABVC public float $37M, Jun 30, 2025
- BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
- Annovis Bio ANVS public float $36M, Jun 30, 2025
- Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025
- Grace Therapeutics GRCE public float $35M, Sep 30, 2025